Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals.

about

High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study.

P2860

Q35736714-21BAB5F9-CA03-45ED-A4AD-355E06257CB5

P2860

Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals.

Item

http://www.wikidata.org/entity/Q45180360

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Aspirin Half Maximal Inhibitor ...... m that of Healthy Individuals.

@en

Aspirin Half Maximal Inhibitor ...... m that of Healthy Individuals.

@nl

type

Item

label

Aspirin Half Maximal Inhibitor ...... m that of Healthy Individuals.

@en

Aspirin Half Maximal Inhibitor ...... m that of Healthy Individuals.

@nl

prefLabel

Aspirin Half Maximal Inhibitor ...... m that of Healthy Individuals.

@en

Aspirin Half Maximal Inhibitor ...... m that of Healthy Individuals.

@nl

P1476

Aspirin Half Maximal Inhibitor ...... m that of Healthy Individuals.

@en

P2093

Kaneo Satoh

http://www.w3.org/2001/XMLSchema#string

Kaoru Aida

http://www.w3.org/2001/XMLSchema#string

Katsuhiro Takano

http://www.w3.org/2001/XMLSchema#string

Tetsuro Kobayashi

http://www.w3.org/2001/XMLSchema#string

Yukio Kimura

http://www.w3.org/2001/XMLSchema#string

Yukio Ozaki

http://www.w3.org/2001/XMLSchema#string

P2860

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study

Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

Aspirin resistance

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment

P304

629-636

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1076029613488934

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23677911

http://www.w3.org/2001/XMLSchema#string

P921

aspirin

Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals.

about

P2860

P2860

Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921